Van Eck Associates Corp Novo Cure LTD Transaction History
Van Eck Associates Corp
- $77.4 Billion
- Q1 2025
A detailed history of Van Eck Associates Corp transactions in Novo Cure LTD stock. As of the latest transaction made, Van Eck Associates Corp holds 22,384 shares of NVCR stock, worth $260,549. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,384
Previous 21,059
6.29%
Holding current value
$260,549
Previous $628,000
36.46%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding NVCR
# of Institutions
261Shares Held
79.3MCall Options Held
970KPut Options Held
118K-
Black Rock Inc. New York, NY12.1MShares$141 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$131 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA8.95MShares$104 Million0.03% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT5.52MShares$64.3 Million8.14% of portfolio
-
Capital World Investors Los Angeles, CA5.22MShares$60.7 Million0.02% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.22B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...